COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,304 Articles (22,772 medRxiv, 8,532 bioRxiv)

Most recent first Previous |  Page 842: Articles 8411-8420  | Next

Serious underlying medical conditions and COVID-19 vaccine hesitancy.
Day, D., Grech, L., Nguyen, M., Bain, N., Kwok, A., Harris, S., Chau, H., Chan, B., Blennerhassett, R., Nott, L., Hamad, N., Tognela, A., Hoffman, D., McCartney, A., Webber, K., Wong, J., Underhill, C., Sillars, B., Winkel, A., Savage, M., Loe, B. S., Freeman, D., Segelov, E., CANVACCS, DIABVACCS, and MSVACCS investigators
10.1101/2022.04.06.22273080 — Posted: 2022-04-06
Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine
Romero-Ibarguengoitia, M. E., Gonzalez-Cantu, A., Rivera-Salinas, D., Hernandez-Ruiz, Y. G., Armendariz-Vazquez, A. G., Barco-Flores, I. A., Gonzalez-Facio, R., Sanz-Sanchez, M. A.
10.1101/2022.04.05.22273434 — Posted: 2022-04-06
Monitoring of SARS-CoV-2 variant dynamics in wastewater by digital RT-PCR : from Alpha to Omicron BA.2 VOC
Wurtzer, S., Levert, M., Dhenain, E., Accrombessi, H., Manco, S., Fagour, N., Goulet, M., Boudaud, N., Gaillard, L., Bertrand, I., Challant, J., Masnada, S., Azimi, S., Gillon-Ritz, M., Robin, A., Mouchel, J.-M., SIG OBEPINE, , Moulin, L.
10.1101/2022.04.04.22273320 — Posted: 2022-04-06
Predictors for Reactogenicity and Humoral Immunity to SARS-CoV-2 Following Infection and mRNA Vaccination: A Regularized Mixed-Effects Modelling Approach
Williams, E., Kizhner, A., Stark, V. S., Nawab, A., Muniz, D. D., Echeverri Tribin, F., Carreno, J. M., Bielak, D., Singh, G., Hoffer, M. E., Pallikkuth, S., Pahwa, S.
10.1101/2022.04.05.22273450 — Posted: 2022-04-06
Antibody responses to SARS-CoV-2 vaccination in patients with acute leukaemia and high risk MDS on active anti-cancer therapies
Chan, W. Y., Zhu, C., Sanchez, E., Gupta, R., Fielding, A. K., Khwaja, A., Payne, E. M., O'Nions, J.
10.1101/2022.04.05.22273371 — Posted: 2022-04-06
SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: genomic surveillance in Japan from September 2021 to March 2022
Hirotsu, Y., Maejima, M., Shibusawa, M., Natori, Y., Nagakubo, Y., Hosaka, K., Sueki, H., Mochizuki, H., Tsutsui, T., Kakizaki, Y., Miyashita, Y., Omata, M.
10.1101/2022.04.05.22273483 — Posted: 2022-04-06
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
Priddy, F. H., Williams, M., Carson, S., Lavender, B., Mathieson, J., Frampton, C., Moreland, N. J., McGregor, R., Williams, G., Brewerton, M., Gell, K., Ussher, J., Le Gros, G.
10.1101/2022.04.05.22273480 — Posted: 2022-04-06
Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition
Ndhlovu, Z. M., Nkosi, T., Mbatha, A., Nsimbi, M., Papadopoulos, A. O., Nguni, T., Karim, F., Moosa, M. Y. S., Gazy, I., Jambo, K., COMMIT-KZN, , Hanekom, W., Sigal, A.
10.1101/2022.04.05.22273453 — Posted: 2022-04-06
Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management
Johnston, M., Ates, H. C., Glatz, R. T., Mohsenin, H., Schmachtenberg, R., Göppert, N., Huzly, D., Urban, G. A., Weber, W., Dincer, C.
10.1101/2022.03.30.22271928 — Posted: 2022-04-06
Effect of Heat inactivation and bulk lysis on Real-Time Reverse Transcription PCR Detection of the SARS-COV-2: An Experimental Study
Leta, D., Jebessa, G. G., Gebremichael, G., Diriba, R., Bulti, G., Sura, T., Ayana, D., Chala, D., Lenjiso, B., Bulti, J., Abdella, S., Hailu, H. T.
10.1101/2022.04.04.22273334 — Posted: 2022-04-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).